About Eviagenics
Eviagenics is a Healthcare company based in Paris (France) founded in 2004. Seaweed extract ingredients for food and cosmetics are produced. Eviagenics has raised $2.3 million across 2 funding rounds from investors including CEA Investissement, Karista and Demeter. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and In Vitro Assays.
Company details
A biotechnology company known as Eviagenics was founded in 2004 in Paris, France. Seaweed extract ingredients are produced by the company for applications in food and cosmetics. Operations are centered on extracting and processing seaweed-based materials. Previously operated as Eviagenics SARL, ALGANACT was acquired in 2016, after which the name was changed to Algaia. Focus remains on sustainable biotechnology solutions in the sector.
- Headquarters Paris, France
- SectorsHealthcare
- Website eviagenics.com
- Total Equity Funding$2.3M (USD)
in 2 rounds
- Latest Funding Round$1M (USD), Series A
Mar 2015
- InvestorsCEA Investissement
& 2 more
Funding Insights of Eviagenics
Eviagenics has successfully raised a total of $2.3M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $1 million completed in March 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.3M
- Total Rounds 2
- Last Round Series A — $1M
- First Round $1.3M
(Jan 2011)
- Investors Count 3
All 2 funding rounds of Eviagenics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2015 | $1M | Series A | – | – | – |
| Jan 2011 | $1.3M | Series A | – | CEA Investissement, Karista | – |
3 investors in total: 3 institutional.
Investors in Eviagenics
Eviagenics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include CEA Investissement, Karista and Demeter.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in startups are facilitated to valorize CEA technologies. | 1999 | cea-investissement.com | France | |
Karista is recognized as an early-stage venture capital firm. | 2001 | karista.vc | Paris, France | |
Demeter is recognized as a major European investor in venture capital and private equity for energy and ecological transition. | demeter-im.com | Paris, France |
Investor details for Eviagenics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Eviagenics
3 dated milestones of Eviagenics across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Eviagenics is founded.
- Funding First funding round of $1.3M.
- Funding Latest funding round, Series A, of $1.0M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Eviagenics
Eviagenics was founded in 2004 and raised its 1st funding round 7 years after it was founded.
Eviagenics is headquartered in Paris, France.
Eviagenics is a funded company, having raised a total of $2.3M across 2 funding rounds to date. The company's 1st funding round was a Series A of $1.3M, raised on Jan 2011.
A biotechnology company known as Eviagenics was founded in 2004 in Paris, France. Seaweed extract ingredients are produced by the company for applications in food and cosmetics. Operations are centered on extracting and processing seaweed-based materials. Previously operated as Eviagenics SARL, ALGANACT was acquired in 2016, after which the name was changed to Algaia. Focus remains on sustainable biotechnology solutions in the sector.
Eviagenics has 3 investors. Key investors include CEA Investissement, Karista, and Demeter.